Korea Exchange postpones decision on delisting Kolon TissueGene Results of Phase 3 clinical trial in U.S. likely to be key to resumption of stock trading
Translated by Kim So-in 공개 2022-02-10 08:06:25
이 기사는 2022년 02월 10일 08:01 thebell 에 표출된 기사입니다.
The Korea Exchange (KRX), South Korea's bourse operator, has decided to postpone its decision on whether to delist the scandal-ridden drugmaker Kolon TissueGene from the secondary Kosdaq market.A Kosdaq market committee under the KRX decided on Monday to reopen the review meeting, without giving the reason and timeframe.
“We expect the patient dosing in the Phase 3 clinical trial in the U.S. will be completed in 2023,” said an official at Kolon TissueGene. “We have resumed patient dosing on December 28, 2021 despite the Covid-19 pandemic.”
Last year, Kolon TissueGene was given a one-year grace period by the Kosdaq committee for the second time to restore its credibility over phony reporting of its gene therapy drug Invossa and avoid delisting from the Kosdaq market. The trading of Kolon TissueGene stock has been suspended since 2019.
Upon the committee’s latest call, the final decision will be made in September or October, with the drugmaker’s submission of additional document.
Kolon TissueGene is required to submit an improvement plan and an expert’s verification on the plan within 15 business days from the expiry date of August 31. The KRX will hold a corporate review committee within 29 business days from the document submission date and make the final decision.
Whether the company will be delisted depends on the results of the Phase 3 clinical trial in the U.S. The key to the resumption of the trading is whether Kolon TissueGene can submit a statistically significant Phase 3 clinical trial interim results to the KRX. (Reporting by Sook Hong)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- '재무개선' AJ네트웍스, 조달비용 '확' 낮췄다
- '9년만에 엑시트' 한앤코, 한온시스템 거래구조 살펴보니
- 한국타이어앤테크놀로지, 한온시스템 인수한다
- [수술대 오른 커넥트웨이브]2대주주 지분매입 나선 MBK, 주식교환 카드 꺼냈다
- [이사회 모니터]이재용 에이비프로바이오 대표, 바이오·반도체 신사업 '드라이브'
- 와이투솔루션, 주인 바뀌어도 '신약' 중심엔 美 합작사 '룩사'
- 아이티센, 부산디지털자산거래소 본격 출범
- 아이에스시, AI·데이터센터 수주 증가에 '날개'
- [이사회 모니터]서정학 IBK증권 대표, ESG위원회도 참여 '영향력 확대'
- SW클라우드 '10주년' 폴라리스오피스, “초격차 밸류업”